🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy cardiologist just high-fived me at my checkup lol — July 2024 Page 2

My cardiologist just high-fived me at my checkup lol — July 2024

MASHdoc_SA Mon, Feb 2, 2026 at 11:23 PM 39 replies 1,296 viewsPage 2 of 8
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Feb 3, 2026 at 11:52 PM#6
NeuroNate said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

Pushing back on NeuroNate here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

48 1jennifer_SEA, tyler_CSCS, VanRx_Mike and 45 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Feb 4, 2026 at 9:36 AM#7
MASHdoc_SA said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
49 2maya_sedona, stefan_berlin, Dr.EM_Chicago and 46 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Feb 4, 2026 at 7:20 PM#8
KevinCompounds said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.
KevinCompounds said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

50 3tampaLisa73, KarenAZ_mom, zoe_NC and 47 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Feb 5, 2026 at 5:04 AM#9

A narrower follow-up, since the general answer is now clear:

How long did you give it before you decided it was working?

1 4PurityPaulOR
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Feb 7, 2026 at 3:45 AM#10
Dr.ObesityLA said:
KevinCompounds said: ...we don't know the long-term effects of cardiovascular risk...

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

31 6kate.chem, DataDave, Dr.GutHealth and 28 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register